Develops biologic therapies for cancer and rare diseases using multiple antibody engineering platforms.
Develops biologic therapies for cancer and rare diseases using multiple antibody engineering platforms.
Has no approved product, so it earns nothing from sales and is funded by cash raised from investors. It was formed in 2024 when Sanofi bought Inhibrx's alpha-1 antitrypsin programme, and the rest of the pipeline, led by its cancer antibody candidates, was spun off as a separate listed company.
Moat: none (IP / patents). Diversified biologics pipeline across multiple engineering platforms, but no approved products yet.
Headquarters: La Jolla, California, US · Founded: 2010 · Employees: 110
Size Inhibrx Biosciences (INBX) is a United States Health Care company (Biotechnology) with a market value of $1.02B, the 2222nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $69.06 on 18 Nov 2026.
Performance Over six months the shares fell 37.2%, against -15.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 42.9% over the last twelve months (peer median +1.1%); the operating margin is -6,286.7% (peer median -18.4%).
Valuation It trades at 551.0× enterprise value to sales against a peer median of 6.2× (most expensive of 14).
Short interest Short interest is 23.0% of the free float (30 Oct 2026).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.00M | $1.30M | $200,000 | $1.80M | $2.19M |
| Revenue growth | — | +550% | -89% | -18% | — |
| Gross profit | -$138,000 | -$1.18M | -$2.08M | $609,000 | n/a |
| EBITDA | -$124M | -$133M | -$329M | -$218M | -$128M |
| Net income | -$142M | -$140M | $1.69B | -$241M | -$145M |
| Free cash flow | -$133M | -$130M | -$197M | -$198M | -$116M |
| Capital expenditure | $29,000 | $31,000 | $2.60M | $4.59M | $686,000 |
| Total debt | $281M | $107M | $8.05M | $210M | $207M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Inhibrx Biosciences INBX | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a |
| Grifols GRF.MC | $7.48B | +19% | +1% | 16% | 2.4× | 7.1% |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INBX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.5% | -7.5% | 4th lowest of 21 |
| 6-month return | -37.2% | -15.1% | 3rd lowest of 20 |
| Distance from 52-week high | -55.5% | -38.9% | 3rd lowest of 21 |
| Revenue growth (TTM) | +42.9% | +1.1% | 3rd highest of 14 |
| Operating margin | -6,286.7% | -18.4% | lowest of 14 |
| EV / Sales | 551.0× | 6.2× | most expensive of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 2.9× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | 8.0× | 4.8% | -32.3% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |